Three Ways GLP-1 Drugs Could Be Improving

The enormous popularity of new weight-loss drugs often eclipses the downsides: the burden of weekly injections, rough gastrointestinal side effects, muscle and bone loss.

That is shaping a race among drug manufacturers vying to roll out better options.

Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, which makes Ozempic and Wegovy, have the vast market for branded drugs to themselves and are steadily reaping billions of dollars. But pharmaceutical giants Pfizer, Roche, Boehringer Ingelheim and Amgen are among competitors planning to bring improved drugs to the market.

Please select this link to read the complete article from The Washington Post.